Home
Solutions
Products
Pricing
Resources
Request Demo
Start Free
Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo
StateStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

  • 1459 new people
  • 45 new organizations
  • 1484 new photos
  • 1777 job history records for people in our database
  • 597 education records for people in our database
  • 2910 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
  • 2 new people through the revolving door
  • 257 new policy reports
  • 19 new trips to our privately funded travel database
  • 13056 new press releases
  • 19 new town halls

Caught Our Eye Rss

» More from Caught Our Eye
» More from our DevBlog

H.R. 2355, Opioid Prescription Verification Act of 2021 (CBO Report for Congress)

Premium   Download PDF Now (1 page)
Congress 117th
Date Requested July 21, 2021
Requested By House Committee on Energy and Commerce
Date Sent Sept. 21, 2021
Description:
H.R. 2355 would require the Secretary of Health and Human Services to update materials that provide guidance for pharmacists, health care providers, and patients about when a pharmacist may decline to fill a prescription for a controlled substance. The updated materials would include information for pharmacists on how to verify the identity of the patient. Based on historical spending patterns for similar activities, CBO estimates that costs to the federal government of developing and distributing those materials would not be significant. The bill would also specify criteria the Director of the Centers for Disease Control and Prevention may use when determining amounts for grants to state, local, and tribal governments to prevent overdoses of controlled substances. Those new criteria could affect the amounts awarded to a specific entity, but CBO estimates they would not affect the total amount of grants awarded; therefore, the provision would have no federal budgetary effect.  

« Return to search CBO reports

HomeAbout Us Contact UsPrivacy PolicyTerms of UseJoin Us
© LegiStorm
LegiStorm
2101 L St. NW, Suite 300
Washington, DC 20037
(202) 360-4172 / congress@legistorm.com